作者
Guy A Van Hazel, Volker Heinemann, Navesh K Sharma, Michael PN Findlay, Jens Ricke, Marc Peeters, David Perez, Bridget A Robinson, Andrew H Strickland, Tom Ferguson, Javier Rodríguez, Hendrik Kröning, Ido Wolf, Vinod Ganju, Euan Walpole, Eveline Boucher, Thomas Tichler, Einat Shacham-Shmueli, Alex Powell, Paul Eliadis, Richard Isaacs, David Price, Fred Moeslein, Julien Taieb, Geoff Bower, Val Gebski, Mark Van Buskirk, David N Cade, Kenneth Thurston, Peter Gibbs
发表日期
2016/5/20
期刊
Journal of Clinical Oncology
卷号
34
期号
15
页码范围
1723-1731
出版商
American Society of Clinical Oncology
简介
Purpose
SIRFLOX was a randomized, multicenter trial designed to assess the efficacy and safety of adding selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres to standard fluorouracil, leucovorin, and oxaliplatin (FOLFOX)–based chemotherapy in patients with previously untreated metastatic colorectal cancer.
Patients and Methods
Chemotherapy-naïve patients with liver metastases plus or minus limited extrahepatic metastases were randomly assigned to receive either modified FOLFOX (mFOLFOX6; control) or mFOLFOX6 plus SIRT (SIRT) plus or minus bevacizumab. The primary end point was progression-free survival (PFS) at any site as assessed by independent centralized radiology review blinded to study arm.
Results
Between October 2006 and April 2013, 530 patients were randomly assigned to treatment (control, 263; SIRT, 267). Median PFS at any site was 10.2 v 10.7 months in …
学术搜索中的文章
GA Van Hazel, V Heinemann, NK Sharma… - Journal of Clinical Oncology, 2016